Healthcare / Medical Care FacilitiesBSE
$374.15
-11.60 (-2.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.2B · quality 81.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$34.3B
P/E
18.7x
↓EV/EBITDA
11.7x
↓ROE
24.8%
↑Gross Margin
37.0%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+11.7%
FCF CAGR
+2.6%
FCF margin
7.3%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.83B · net income $1.84B · FCF $1.08B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.83B | $14.83B | $13.56B | $12.04B | $10.65B |
| Net Income | $1.84B | $1.84B | $1.61B | $1.24B | $861.5M |
| EBITDA | $2.96B | $2.96B | $2.67B | $2.07B | $1.57B |
| EPS | — | — | 17.56 | 13.52 | 9.40 |
| Gross Margin | 37.0% | 37.0% | 36.4% | 35.1% | 32.4% |
| Operating Margin | 15.1% | 15.1% | 14.7% | 13.6% | 10.5% |
| Net Margin | 12.4% | 12.4% | 11.9% | 10.3% | 8.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.07 | 0.01 |
| Current Ratio | 2.46 | 2.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.08B | $1.08B | $1.20B | $1.31B | $998.9M |
| Returns | |||||
| ROE | 24.8% | 24.8% | 27.0% | 25.9% | 22.7% |
| Valuation | |||||
| P/E | 18.69 | 18.69 | 22.50 | 18.05 | 8.55 |
| EV/EBITDA | 11.71 | 11.71 | 13.46 | 10.66 | 4.38 |
| P/B | 4.63 | 4.63 | 6.07 | 4.68 | 1.94 |
| Growth & Yield | |||||
| Revenue Growth | 9.3% | 9.3% | 12.6% | 13.1% | — |
| EPS Growth | — | — | 29.9% | 43.8% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.0%
Start / end P/E
n/dx → n/dx
EPS bridge
17.56 → n/d
Residual
-8.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.